ARK Genomic Revolution ETF vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.49, while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.62. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | EMLC | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $44.55 | $26.59 |
52-Week Low | $24.02 | $24.83 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →